Apremilast and Moderate to Severe Chronic Hand Dermatitis
Part of paid clinical trials in Washington D.C., District of Columbia.
- Sponsor
- George Washington University
- Study ID
- NCT03741933
- Phase
- PHASE4
- Status
- Withdrawn
Conditions
- Chronic Hand Dermatitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 79 Years
- Healthy Volunteers
- Accepted
Interventions
- Apremilast 30mg — DRUGApremilast 30 mg tablet
Study Details
Investigators have designed a pilot study involving chronic hand dermatitis (CHD) patients who attend the dermatology clinic at the George Washington Medical Faculty Associates (GW MFA) in order to assess the efficacy and safety of apremilast treatment for the treatment of moderate to severe CHD.
Key Dates
- First listed
- Nov 15, 2018
- Start date
- Feb 28, 2019
- Status verified
- Jan 2023
- Primary completion
- Aug 1, 2019
- Completion
- Aug 1, 2019
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Apremilast30 mg twice daily to be administered for a period of 6 months
Primary Outcome Measure
To evaluate the efficacy of Apremilast 30mg twice daily administered as monotherapy in the treatment of moderate-to-severe CHD as assessed by improvement of the Physician Global Assessment (PGA). [ Time Frame: 24 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| George Washington University Department of Dermatology | Washington D.C. | District of Columbia | 20037 | - |